1/53
Looks like no tags are added yet.
Somatic nervous system function
Voluntary control of skeletal muscles and sensory input.
Autonomic nervous system (ANS) function
Involuntary control of internal organs, smooth muscle, heart, and glands.
Sympathetic neurotransmitter
Noradrenaline (norepinephrine) and adrenaline (epinephrine).
Parasympathetic neurotransmitter
Acetylcholine (ACh).
Airway effect of sympathetic stimulation
Bronchodilation via β2 adrenergic receptors.
Airway effect of parasympathetic stimulation
Bronchoconstriction and mucus secretion via M3 muscarinic receptors.
Catecholamine structure
A catechol ring (benzene with two adjacent hydroxyls) plus an amine.
Rate-limiting enzyme in noradrenaline synthesis
Tyrosine hydroxylase, which is inhibited by noradrenaline feed-back.
Location of adrenaline synthesis
Adrenal medulla, via the enzyme phenylethanolamine-N-methyltransferase (PNMT).
Noradrenaline termination mechanisms
Reuptake by transporters and intracellular metabolism by MAO and COMT.
Acetylcholine termination mechanism
Rapid enzymatic breakdown by acetylcholinesterase in the synapse.
α1 adrenergic receptor coupling
Gq-coupled; activates phospholipase C, increasing intracellular calcium.
α2 adrenergic receptor coupling
Gi-coupled; inhibits adenylate cyclase, decreasing cAMP.
β adrenergic receptor coupling
Gs-coupled; activates adenylate cyclase, increasing cAMP.
β1 receptor location and function
Heart (increases rate and contractility) and kidney (renin release).
β2 receptor location and function
Lungs (bronchodilation) and vascular smooth muscle (vasodilation).
Odd-numbered muscarinic receptors (M1, M3, M5) coupling
Excitatory; Gq-coupled, increasing IP3 and intracellular calcium.
Even-numbered muscarinic receptors (M2, M4) coupling
Inhibitory; Gi-coupled, decreasing cAMP.
Key muscarinic receptor subtype in the airways
M3 receptor.
Adrenergic receptor SAR: N-substituent size
Large substituents (e.g., isopropyl) give β-selectivity; small substituents favor α-activity.
Adrenergic receptor SAR: Ring substitution for COMT resistance
Requires 3',5'-diOH (resorcinol) or 3'-CH2OH, 4'-OH (saligenin) instead of catechol.
Isoprenaline selectivity and stability
β-selective (large N-isopropyl) but non-selective between β1/β2; COMT-labile.
Metaproterenol (Orciprenaline) structural hallmark
Resorcinol ring (3',5'-diOH) makes it resistant to COMT metabolism.
Salbutamol structural hallmark
Saligenin ring (3'-CH2OH, 4'-OH) makes it COMT-resistant.
Structural feature of LABAs and Ultra-LABAs
Long, lipophilic N-substituents that anchor the drug in the cell membrane.
Formoterol vs. Salmeterol onset
Formoterol has rapid onset; Salmeterol has slower onset.
SABA vs. LABA dosing frequency
SABAs are used as-needed; LABAs are dosed twice daily.
Ultra-LABA dosing frequency
Once daily, due to duration of 24 hours or longer.
Airway effects of M3 antagonists
Prevent bronchoconstriction and inhibit excess mucus secretion.
Quaternary ammonium nitrogen in antimuscarinics
Prevents crossing the blood-brain barrier, reducing central side effects.
Ipratropium (SAMA) duration and selectivity
Short-acting (4-6 hours); non-selective M1, M2, and M3 blocker.
Tiotropium (LAMA) kinetic selectivity
Dissociates very slowly from M3 but rapidly from M2 (autoreceptor).
Antimuscarinic SAR: R1 and R2 ring requirement
Two aromatic or heterocyclic rings maximize potency and slow dissociation.
Main maintenance therapy for COPD
LAMA (first-line) or LAMA/LABA combination.
Main maintenance therapy for Asthma
Inhaled Corticosteroid (ICS) first-line; LAMAs are add-on only.
Rationale for LABA + LAMA in COPD
Complementary mechanisms: LABA increases cAMP; LAMA blocks IP3/calcium pathway.
Mechanism of non-selective β-blockers causing bronchospasm
Block β2 receptors in the lungs, opposing bronchodilation.
Organophosphate toxicity mechanism
Irreversibly phosphorylate acetylcholinesterase, leading to acetylcholine accumulation.
Organophosphate poisoning antidotes
Atropine (blocks muscarinic receptors) and pralidoxime (reactivates acetylcholinesterase).
REM sleep muscle atonia
Loss of skeletal muscle tone; worsens airway collapse in OSA.
Obstructive Sleep Apnoea (OSA) vs. Central Sleep Apnoea (CSA) on PSG
OSA shows continued thoracic/abdominal effort; CSA shows no respiratory effort.
Diagnostic gold standard for sleep apnoea
Polysomnography (PSG).
Type II sleep study characteristics
Portable home study with at least 7 channels; diagnostic.
Apnoea-Hypopnoea Index (AHI) calculation
Total apnoeas and hypopnoeas divided by total sleep time in hours.
Moderate OSA AHI range
15 to 29 events per hour.
Severe OSA AHI range
30 or more events per hour.
CPAP mechanism of action
Delivers continuous positive air pressure to splint the upper airway open.
CPAP adherence target
At least 4 hours per night.
Tirzepatide mechanism of action in OSA
Dual GIP/GLP-1 receptor agonist; reduces body weight and AHI.
Pcrit (critical closing pressure)
Pharyngeal pressure at which the upper airway collapses.
Medicines that can worsen OSA
Anticholinergics, sedatives, benzodiazepines, opioids, and alcohol.
OSA50 screening tool score for high probability
A score of 5 or more out of 10.
Epworth Sleepiness Scale severe range
A score of 16 to 24.
Remedy for runny nose after starting CPAP
Add heating and humidification to the CPAP circuit.